COVID-19 Pandemic and Posttreatment Breast Cancer Surveillance and Outcomes

Erin E Hahn; Sarah Eng; Aiyu Chen; Eric C Haupt; Shannon Goodall; Corrine E Munoz-Plaza; Huong Q Nguyen; Michael K Gould; Patricia A Ganz; Ernest Shen

doi:10.1001/jamaoncol.2025.1991

COVID-19 Pandemic and Posttreatment Breast Cancer Surveillance and Outcomes

JAMA Oncol. 2025 Sep 1;11(9):1091-1093. doi: 10.1001/jamaoncol.2025.1991.

Authors

Erin E Hahn^{1

2}, Sarah Eng^{1

3}, Aiyu Chen¹, Eric C Haupt¹, Shannon Goodall⁴, Corrine E Munoz-Plaza¹, Huong Q Nguyen^{1

2}, Michael K Gould², Patricia A Ganz^{5

6}, Ernest Shen¹

Affiliations

¹ Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena.
² Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.
³ Truveta Inc, Bellevue, Washington.
⁴ Department of Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, Louisiana.
⁵ Jonsson Comprehensive Cancer Center at University of California, Los Angeles, Los Angeles.
⁶ University of California, Los Angeles Fielding School of Public Health, Los Angeles.

PMID: 40674101
PMCID: PMC12272353 (available on 2026-07-17)
DOI: 10.1001/jamaoncol.2025.1991

No abstract available

Plain language summary

This Research Letter compares use of surveillance imaging in pre–COVID-19 and post–COVID-19 periods for patients with an early-stage breast cancer diagnosis within a large integrated health care system.

Grants and funding

R01 CA249419/CA/NCI NIH HHS/United States